Glenmark to launch generic cancer drug Eribulin Mesylate in US

Glenmark Pharmaceuticals Inc., USA, announced its upcoming launch of Eribulin Mesylate Injection, 1mg/2 mL (0.5 mg/mL) Single-Dose Vials, with distribution commencing in September 2025. This new offering is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven® Injection, 1 mg/2 mL (0.5 mg/mL), from Eisai, Inc.

The launch is significant for Glenmark as it represents the company’s first complex generic in its portfolio. According to IQVIA® sales data for the 12-month period ending July 2025, the market for Halaven® Injection, 1 mg/2 mL (0.5 mg/mL), achieved annual sales of approximately $66.3 million.

Marc Kikuchi, president & business head, North America, stated that this launch underscores Glenmark's commitment to expanding its product offerings within the institutional channel and delivering quality, affordable alternatives to patients in need. Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company focusing on respiratory, dermatology, and oncology.